Ryeqo – A Novel Approach for the Symptomatic Treatment of Uterine Fibroids with Professor Neil Johnson

Prof Neil Johnson will be discussing the clinical trials for the newly available treatment for symptomatic uterine fibroids in New Zealand, Ryeqo. He will delve into the clinical trial results for this oral treatment containing Relugolix, a GnRH antagonist, with add-back therapy (estradiol & norethisterone acetate), including both efficacy and safety data, and longer-term outcomes. This data will be related back to clinical practice and there will be an opportunity for Q&A with the audience.